Genetic alteration in the dopamine transporter differentially affects male and female nigrostriatal transporter systems

Biochemical Pharmacology

Volumn 78, Issue 11, 2009, Pages 1401-1411

  Ji, Jing ^a,b   Bourque, Mélanie ^c,d   Di Paolo, Thérèse ^c,d   Dluzen, Dean E ^a  

^a Northeastern Ohio Medical University   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Corpus striatum; Drug addiction; Parkinson's disease; Sex dimorphism; Vesicular monoamine transporter 2

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; MESSENGER RNA; RESERPINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DEPENDENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; HETEROZYGOTE; MALE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SEX DIFFERENCE; SUBSTANTIA NIGRA;

ANIMALS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; MALE; MICE; MICE, MUTANT STRAINS; PROTEIN BINDING; RESERPINE; RNA, MESSENGER; SEX CHARACTERISTICS; SUBSTANTIA NIGRA; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 70349772956     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.07.004     Document Type: Article

References (50)

1. Riddle E.L., Fleckenstein A.E., and Hanson G.R. Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7 (2005) E847-E851
2. Giros B., Jaber M., Jones S.R., Wightman R.M., and Caron M. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379 (1996) 606-612
3. Kantor L., and Gnegy M.E. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 284 (1998) 592-598
4. Kopin I.J., and Markey S.P. MPTP toxicity: implications for research in Parkinson's disease. Ann Rev Neurosci 11 (1988) 81-96
5. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., and Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13 (1990) 290-296
6. Kitayama S., Shimada S., and Uhl G.R. Parkinsonism inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann Neurol 32 (1992) 109-111
7. Pifl C., Giros B., and Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13 (1993) 4246-4253
8. Dluzen D.E., Disshon K.A., and McDermott J.L. Estrogen as a modulator of striatal dopaminergic neurotoxicity. In: Marwah J., and Teitelbaum H. (Eds). Recent advances in neurological disorders (1998), Prominent Press, Scottsdale, AZ 149-192
9. Dluzen D.E., and Liu B. Gender differences in methamphetamine use and responses: a review. Gend Med 5 (2008) 24-35
10. Morissette M., and Di Paolo T. Sex and estrous cycle variations of striatal dopamine uptake sites. Neuroendocrinology 58 (1993) 16-22
11. Rivest R., Flardeau P., and Di Paolo T. Brain dopamine transporter: gender differences and effects of chronic haloperidol. Brain Res 692 (1995) 269-272
12. Walker Q.D., Rooney M.B., Wightman R.M., and Kuhn C.M. Dopamine release and uptake are greater in female than male striatum as measured by fast cyclic voltammetry. Neuroscience 95 (2000) 1061-1070
13. Bhatt S.D., and Dluzen D.E. Dopamine transporter function differences between male and female CD-1 mice. Brain Res 1035 (2005) 188-195
14. Lavalaye J., Booji J., Reneman L., Harbraken J.B., and von Royen E.A. Effect of age and gender on dopamine transporter imaging with [123I] FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27 (2000) 867-869
15. Mozley L.H., Gur R.C., Mozley P.D., and Gur R.E. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiat 158 (2001) 1492-1499
16. Staley J.K., Krishnan-Sarin S., Zoghbi S., Tamagnan G., Fujita M., Seibyl J.P., et al. Sex differences in [123I];B-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41 (2001) 275-284
17. Ji J., and Dluzen D.E. Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice. J Neural Transm 115 (2008) 809-817
18. Kanes S.J., Hitzemann B.A., and Hitzemann R.J. On the relationship between D2 receptor density and neuroleptic-induced catalepsy among eight inbred strains of mice. J Pharm Exp Ther 267 (1993) 538-547
19. Helmeste D.M., and Seeman P. Amphetamine-induced hypolocomotion in mice with more brain D2 dopamine receptors. Psychiatric Res 7 (1982) 351-359
20. Severson J.A. Genotypic variation in striatal calmodulin content. Brain Res 340 (1985) 79-86
21. Miller G.W., Gainetdinov R.R., Levey A.I., and Caron M.G. Dopamine transporters and neuronal injury. Tips 20 (1999) 424-429
22. Brown J.M., Hanson G.R., and Fleckenstein A.E. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 296 (2001) 762-767
23. Colburn R.W., and Kopin I.J. Effects of reserpine and tyramine on release of norepinephrine from synaptosomes. Biochem Pharmacol 21 (1972) 733-736
24. Ji J., McDermott J.L., and Dluzen D.E. Sex differences in K+-evoked striatal dopamine output from superfused striatal tissue fragments of reserpine-treated CD-1 mice. J Neuroendocrinol 19 (2007) 725-731
25. Van der Elst M.C.J., Wunderink Y.S., Ellenbrook B.A., and Cools A.R. Differences in the cellular mechanism underlying the effects of amphetamine n prepulse inhibition in apomorphine-susceptible and apomorphine-unsusceptible rats. Psychopharmacology 190 (2007) 93-102
26. Verheij M.M.M., and Cools A.R. Differential contribution of storage pools to the extracellular amount of accumbal dopamine in high and low responders to novelty: effects of reserpine. J Neurochem 100 (2007) 810-821
27. Marshall V., and Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18 (2003) 1415-1423
28. Erixon-Lindroth N., Farde L., Wahlin T.B., Sovago J., Halldin C., and Bäckman L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res 138 (2005) 1-12
29. Fumagalli F., Jones S., Bosse R., Jaber M., Giros B., Nissale C., et al. Inactivation of the dopamine transporter reveals essential roles of dopamine in the control of locomotion, psychostimulant response and pituitary function. Adv Pharmacol 42 (1998) 179-182
30. Uhl G.R., Vandenbergh D.J., and Miner L.L. Drug addiction: knockout mice and dirty drugs. Curr Biol 6 (1996) 935-936
31. Dluzen D.E., and Horstink M. Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies. Endocrine 21 (2003) 67-75
32. Franklin K., and Paxinos G. The mouse brain in stereotaxic coordinates (1997), Academic Press, San Diego
33. Callier S., Morissette M., Grandbois M., Pelaprat D., and Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41 (2001) 131-138
34. Kilbourn M., and Frey K. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur J Pharmacol 307 (1996) 227-232
35. Jourdain S., Morissette M., Morin N., and Di Paolo T. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine mice. J Neuroendocrinol 17 (2005) 509-517
36. Bourque M., Liu B., Dluzen D.E., and Di Paolo T. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity. Biochem Pharmacol 74 (2007) 1413-1423
37. Falardeau P., and Di Paolo T. Regional effect of estradiol on rat caudate-putamen dopamine receptors: lateral-medial differences. Neurosci Lett 74 (1987) 43-48
38. Morissette M., and Di Paolo T. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J Neurochem 60 (1993) 1876-1883
39. Morissette M., Biron D., and Di Paolo T. Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res Bull 25 (1990) 419-422
40. Bosse R., Rivest R., and Di Paolo T. Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res 46 (1997) 343-346
41. Le Saux M., and Di Paolo T. Influence of estrogenic compounds on monoamine transporter in rat striatum. J Neuroendocrin 18 (2006) 25-32
42. Attali G., Weizman A., Gil-Ad I., and Rehavi M. Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters. Brain Res 756 (1997) 153-159
43. McArthur S., Murray H.E., Dhankot A., Dexter D.T., and Gillies G.E. Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormones effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition. J Neurochem 100 (2007) 678-692
44. Glatt C.E., Wahner A.D., White D.J., Ruiz-Linares A., and Ritz B. Gain of function haplotypes in the vesicular monoamine transporter are protective for Parkinson's disease in women. Hum Mol Genet 15 (2006) 299-305
45. Dluzen D.E., Bhatt S.D., and McDermott J.L. Differences in reserpine-induced striatal dopamine output and content between female and male mice: implications for sex differences in vesicular monoamine transporter 2 function. Neuroscience 154 (2008) 1488-1496
46. Dluzen D.E., and Salvaterra T.J. Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: comparisons with potassium-evoked output and responses in prepubertal mice. Neuroendocrinology 82 (2005) 78-86
47. Dluzen D.E., Tweed C., Anderson L.I., and Laping N.J. Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system. Neuroendocrinology 77 (2003) 232-238
48. Wagner G.C., Tekirian T.L., and Cheo C.T. Sexual differences in sensitivity to methamphetamine toxicity. J Neural Transm Gen Sect 93 (1993) 67-70
49. Yu L., and Liao P.C. Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J Neural Transm 107 (2000) 419-427
50. Guillot T.S., Shepherd K.R., Richardson J.R., Wang M.Z., Li Y., Emson P.C., et al. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J Neurochem 106 (2008) 2205-2217